Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.34 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24802684 | 0.84 | GNPAT (0.39) | GNPATFOLH1KMT2APOLBHDAC2 | |
| SCHEMBL21339757 | 0.79 | FOLH1 (0.57) | GNPATFOLH1SIRT2SIRT1SIRT3 | |
| SCHEMBL13674408 | 0.75 | GNPAT (0.56) | GNPATFOLH1NOD1 | |
| SCHEMBL20581567 | 0.73 | CASP2 (0.50) | KMT2APOLBHDAC2NOD1 | |
| SCHEMBL20581569 | 0.73 | CASP2 (0.50) | KMT2APOLBHDAC2NOD1 | |
| SCHEMBL16199279 | 0.72 | KMT2A (0.50) | GNPATKMT2APOLB | |
| SCHEMBL21879809 | 0.72 | NPY4R (0.44) | FOLH1SIRT2SIRT1SIRT3 | |
| SCHEMBL12028772 | 0.70 | GNPAT (0.61) | GNPATFOLH1NOD1 | |
| SCHEMBL29431224 | 0.70 | KMT2A (0.42) | KMT2APOLBHDAC2SIRT2SIRT1 | |
| SCHEMBL17304353 | 0.70 | GNPAT (0.61) | GNPATFOLH1NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409594-A1 | CD4 MIMIC COMPOUND WITH ANTI-HIV ACTIVITY | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409594-A1 | CD4 MIMIC COMPOUND WITH ANTI-HIV ACTIVITY | CD4, CD81, CD14 | GNPAT 3577/4885FOLH1 313/4885KMT2A 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.